
MAZE Stock Forecast & Price Target
MAZE Analyst Ratings
Bulls say
Maze Therapeutics Inc., a clinical-stage biopharmaceutical firm focused on advancing precision medicines for chronic kidney disease, is making significant strides with its lead programs, MZE829 and MZE782, showcasing strong efficacy signals in early trials that could facilitate accelerated regulatory approval. The company's innovative Compass platform enhances its ability to link genetic variants to disease pathways, reinforcing confidence in the potential commercial success of its therapies as the updated ICD-10-CM codes support improved diagnosis and treatment. Furthermore, positive Phase 1 data for MZE782 demonstrates a favorable pharmacokinetic profile and substantial increases in urinary Phe excretion, indicating possible best-in-class positioning and enhancing the company's overall market outlook.
Bears say
Maze Therapeutics Inc. is currently facing significant challenges that contribute to a negative outlook on its stock performance. The company’s investigational drug inaxaplin, linked to observed declines in estimated glomerular filtration rate (eGFR), raises concerns regarding its efficacy, potentially inflating efficacy signals and leading to risk assessments suggesting a potential ~30% downside. Additionally, the adverse effects in patients, including inadequate responses to current prevalent therapies like SGLT2 inhibitors, coupled with the limitations in patient stabilization during clinical evaluations, highlight the uncertainties surrounding the company's therapeutic potential and overall market viability.
This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MAZE Analyst Forecast & Price Prediction
Start investing in MAZE
Order type
Buy in
Order amount
Est. shares
0 shares